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Abstract
Background: Conducted as part of the Urologic Diseases in America project whose aim was to quantify
the burden of urologic diseases on the American public, this study focuses on Veterans Health
Administration (VHA) users as a special population to supplement data on overall prevalence rates and
trends in the United States. Veterans comprise 25% of the male population 18 years or older and
contribute substantially to the overall burden of urologic conditions. The objective of this study is to
describe the prevalence rates and trends of urologic cancers and selected benign conditions from 1999 to
2002 for VHA users.
Methods: VHA administrative files for 1999 – 2002 and Medicare claims files for the same years were
used to identify those who had a diagnosis of qualifying urologic conditions.
Results: Among the conditions evaluated, prostate cancer was listed as a primary diagnosis for 5.4% of
VHA users in 2002, followed in decreasing prevalence by erectile dysfunction (2.9%), renal mass (1.5%),
interstitial cystitis (1.4%), and prostatitis (1.1%). Age-adjusted rates showed significant increases for renal
mass (31%), interstitial cystitis (14%), and erectile dysfunction (8%) between 1999 and 2002. Systematic
variations in prevalence rates and trends were observed by age, race/ethnicity, and region. Those in the
Western region generally had lower age-adjusted prevalence rates and their increases were also slower
than other regions. Addition of Medicare data resulted in large increases (21 to 489%) in prevalence among
VHA users, suggesting substantial amount of non-VA urological care provided to VHA users.
Conclusion: Prevalence rates for many urologic diseases increased between 1999 and 2002, which were
not entirely attributable to the aging of veterans. This changing urologic disease burden has substantial
implications for access to urologic care and treatment capacity, especially in light of the level of urologic
care delivered to veterans by Medicare providers outside the VA. Further study on the factors associated
with these increases and how they affect the patterns, cost, and quality of care in veterans is needed.
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Background
Urologic diseases can result in considerable morbidity,
mortality and healthcare resource utilization [1-5]. An
accurate estimation of their prevalence is crucial in pre-
dicting future costs and demands for related services,
understanding patterns of care and planning for resources
needed to meet the demand.
The objective of this study is to describe the prevalence
rates of urologic cancers and selected benign urologic con-
ditions and their trends between 1999 and 2002 for those
who have been using healthcare from the Veterans Health
Administration (VHA). Conducted as part of the Urologic
Diseases in America (UDA) project whose aim was to
quantify the burden of urologic diseases on the American
public [2-5], this study focuses on VHA users as a special
population to supplement data on overall prevalence
rates and trends in the United States. Veterans comprise
25% of the male population 18 years or older [6] and con-
tribute substantially to the overall burden of urologic con-
ditions. About 3.8 million veterans (14% of all veterans)
used healthcare in the VHA in 2000. The overall preva-
lence of, and patterns of care for urologic conditions may
be seriously underestimated without data from the VHA
[7].
Methods
Data sources and population
The Institutional Review Board of the Edward Hines, Jr.
VA Hospital approved the study. The VHA Medical SAS
Inpatient and Outpatient Datasets [8] for 1999 – 2002
and all Medicare claims files for the same years were used
to identify those who were diagnosed with qualifying uro-
logic diseases by VHA or Medicare providers during the
four years [9-12].
For each year, the study population consisted of all VHA
users of age 18 years or older who were veterans and used
either inpatient or outpatient care in the VHA in the cur-
rent or previous year.
Because some of the urologic conditions may occur
almost entirely among individuals of a certain age range
or gender, the base population was specifically defined for
each disease and only the appropriate base population
was searched to identify individuals diagnosed with a dis-
ease. For erectile dysfunction, peyronie's disease, infertil-
ity, undescended testis, hypospadias, prostatitis, and testis
cancer, the base population was all male VHA users. For
prostate cancer, the base population was further limited to
male users aged 40 or older, and for bladder cancer, all
users aged 40 or older. For all other conditions, it was all
users 18 years or older.
Identification of urologic conditions
In this study, 13 urologic conditions selected for Phase 3
of the UDA project, excluding four perinatal conditions
that are not applicable to the VHA user population, were
examined [3]. Five other urologic conditions had been
studied at earlier phases and their results published [4,5].
Both  International Classification of Diseases, 9th  Version,
Clinical Modification (ICD-9-CM) diagnostic and proce-
dure codes for inpatient records and ICD-9-CM diagnostic
codes and Common Procedure Terminology, 4th  Version
(CPT-4) procedure codes for outpatient records were used
to detect conditions. A complete list of diagnostic and
procedure codes used to identify patients with qualifying
conditions is shown in the Appendix (see Additional file
1).
Demographic variables
Prevalence rates and trends were characterized by age,
race/ethnicity, gender, non-VA insurance status, and
region of the country. Age was computed using veterans'
dates of birth as age on January 1st of each year. Race/eth-
nicity data were obtained from the VHA files and, when
missing, were supplemented by those in the Medicare
Denominator files [13].
Non-VA insurance status was obtained from the VHA Out-
patient Medical SAS Datasets and was determined in five
categories, including those with no insurance (self-pay),
Medicare, Medicaid, private insurance, and other insur-
ance.
Region was coded separately for each year based on where
the healthcare episodes occurred, not where the patient
resided. However, if a veteran received healthcare from
providers in two or more regions in the same year, region
was assigned based on the patient's zipcode of residence.
Patients were grouped into four regions, Northeast, Mid-
west, South, and West, as defined by the U.S. Census
Bureau [14].
Statistical analysis
Prevalence rates were calculated as the ratio of all persons
in the base population to the persons having a qualifying
condition listed as a primary diagnosis in a given year.
These rates were all age-adjusted to the 2000 VHA popu-
lation using direct standardization [15,16]. To examine
disease trends, we computed percent change in prevalence
rates for the eight most prevalent diseases using 1999 rates
as the base and the trends were tested for statistical signif-
icance using Mantel-Haenszel chi-square test for trend
[17]. All computation of prevalence rates and trends were
conducted using SAS version 9.3.BMC Urology 2006, 6:30 http://www.biomedcentral.com/1471-2490/6/30
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Results
Overall prevalence rates and trends
Table 1 shows raw counts and age-adjusted prevalence
rates per 100,000 VHA users of selected urologic condi-
tions listed as primary diagnoses for years 1999 – 2002.
The base population of all VHA users (18 years or older)
was 3.7 million in 1999 increasing to 4.8 million in 2002.
This represents a 28% increase over the four year period.
All other base populations showed the same upward
trends as the overall population. The average age of VHA
users increased from 58.9 years in 1999 to 62.0 years in
2002. About 43% of VHA users were elderly (65 or older)
in 1999, while 49% were in 2002.
Among the conditions studied, prostate cancer was the
most common urologic disease in 2002 (5,434/100,000
in the base population), followed by erectile dysfunction
(2,884/100,000), renal mass (1,584/100,000), interstitial
cystitis (1,358/100,000), prostatitis (1,128/100,000), and
bladder cancer (943/100,000).
Conditions such as erectile dysfunction and renal mass
were detected mainly as secondary diagnoses (data not
shown). While 60% of all renal mass cases were listed as
a secondary diagnosis for all four years, increasingly
higher percentage of erectile dysfunction cases were listed
as a secondary diagnosis from 33% in 1999 to 54% in
2002. In contrast, only about 20% of all cancers consid-
ered in this study were listed as secondary diagnoses (data
not shown).
Over the four-year period, renal mass (31%; chi-square
test for trend, p < 0.01), interstitial cystitis (14%; p <
0.01), erectile dysfunction (8%; p = 0.03), kidney cancer
(7%; p = 0.87), and prostate cancer (4%; p = 0.09) showed
increases in age-adjusted rates, although not all were sta-
tistically significant. Prostatitis and urethral stricture
decreased by 10% and 13% over the same period, respec-
tively.
The changes in crude rates were even larger. Most notably,
all three cancers increased 10% or more (data not shown).
Raw counts increased much more rapidly than rates.
Between 1999 and 2002, raw counts increased by 48% for
renal mass, 38% for interstitial cystitis, 36% for prostate
cancer, 35% for kidney cancer, 33% for bladder cancer,
30% for erectile dysfunction, 21% for urethral stricture,
and 20% for prostatitis (chi-square tests for trend, p < 0.01
for all conditions).
Rates and trends by selected demographic categories
Table 2 shows prevalence rates in 2002 and their four-year
changes from 1999 to 2002 of the eight most prevalent
urologic conditions by selected demographic categories.
Rates for all variables other than age are age-adjusted
using 2000 as the reference year.
Age-specific rates indicate that the prevalence generally
increased with age for all conditions. The largest increases
in prevalence rates occurred among those who were 75 or
older for five of the eight conditions. In contrast, prostati-
tis and urethral stricture were decreasing for all but one
age group (85 +). The diagnosis of erectile dysfunction
increased for all but one age group and the largest relative
increase was observed for those younger then 45 years of
age.
Large gender differences in prevalence among VHA users
were found for bladder cancer, kidney cancers, renal mass,
and urethral stricture; all of them were more than 3 times
more prevalent among male than female users. Interstitial
cystitis by contrast was almost twice as prevalent among
female than male users.
There were considerable variations in prevalence across
race/ethnicity groups. Of all groups, Whites had the high-
est prevalence in six of the eight conditions and Blacks
had the highest in the other two conditions, erectile dys-
function and urethral stricture. The rates of bladder cancer
and interstitial cystitis were respectively 2.4 and 1.6 times
more prevalent among Whites than among the next most
prevalent group, ''Others'' (1,222 vs. 507 per 100,000; p <
0.001) for bladder cancer, and Blacks for interstitial cysti-
tis (1,735 vs. 1,103 per 100,000; p < 0.001). The rates for
prostate cancer were over 6,000/100,000 for both Whites
and Blacks, but those for Hispanic and Other groups were
lower than 4,000/100,000. The rates of urethral stricture
were considerably higher than 500/100,000 for Whites
and Blacks but lower than 400/100,000 for Hispanics and
Others.
VHA users who were also Medicare beneficiaries showed
the highest prevalence rates for all of the eight conditions,
consistent with the rates for those in 65 or older age
groups. Those with Medicaid showed the most rapid
increase in prevalence for prostate cancer (16%), kidney
cancer (21%), renal mass (24%), and erectile dysfunction
(18%). Those with no insurance or Medicaid coverage
had the highest increases in prevalence of erectile dysfunc-
tion of all groups.
VHA users who obtained healthcare in the Northeast
region had the highest prevalence rates for prostate can-
cer, bladder cancer, kidney cancer, interstitial cystitis,
while those living in the West region consistently showed
the lowest rates for six of the eight conditions. The West
region also showed the lowest increases in prevalence in
seven of eight conditions. For erectile dysfunction, theB
M
C
 
U
r
o
l
o
g
y
 
2
0
0
6
,
 
6
:
3
0
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
4
9
0
/
6
/
3
0
P
a
g
e
 
4
 
o
f
 
1
1
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 1: Counts and Age-Adjusted Prevalence Rates of Urologic Conditions Listed As Primary Diagnosis, 1999 – 2002*
Conditions 1999 2000 2001 2002
Count Age Adjusted Rate 
(95% CI)
Count Age Adjusted Rate 
(95% CI)
Count Age Adjusted Rate 
(95% CI)
Count Age Adjusted Rate 
(95% CI)
Male reproductive health
Erectile Dysfunction 93,837 2,669 (2,652 – 2,685) 105,481 2,790 (2,773 – 2,807) 118,375 2,805 (2,788 – 2,822) 133,100 2,884 (2,867 – 2,901)
Peyronie's Disease 1,399 40 (38 – 42) 1,501 40 (38 – 42) 1,482 35 (33 – 37) 1,548 33 (31 – 35)
Infertility 2,751 75 (72 – 78) 2,822 75 (72 – 77) 3,051 76 (73 – 79) 3,146 74 (72 – 77)
Undescended Testis 235 7 (6 – 7) 252 7 (6 – 7) 286 7 (6 – 8) 227 5 (4 – 6)
Urethral diseases
Hypospadias 269 8 (7 – 9) 263 7 (6 – 8) 291 7 (6 – 8) 308 7 (6 – 7)
Stricture 15,570 439 (432 – 445) 16,303 412 (406 – 418) 17,768 387 (381 – 393) 19,751 383 (377 – 389)
Interstitial Cystitis 42,638 1,195 (1,184 – 1,206) 49,710 1,256 (1,245 – 1,267) 61,500 1,344 (1,332 – 1,355) 69,469 1,358 (1,347 – 1,370)
Prostatitis 43,257 1,254 (1,243 – 1,266) 45,362 1,200 (1,189 – 1,211) 52,005 1,204 (1,193 – 1,215) 53,877 1,128 (1,118 – 1,139)
Prostate cancer 159,800 5,226 (5,202 – 5,250) 180,633 5,232 (5,208 – 5,256) 217,997 5,373 (5,349 – 5,398) 247,914 5,434 (5,409 – 5,459)
Bladder Cancer 29,725 938 (928 – 948) 33,016 926 (916 – 936) 39,345 942 (932 – 952) 44,397 943 (933 – 953)
Kidney Cancer 7,777 217 (213 – 222) 8,692 220 (215 – 224) 10,345 227 (222 – 231) 11,878 233 (229 – 238)
Renal Mass 42,725 1,209 (1,198 – 1,220) 52,117 1,317 (1,305 – 1,328) 66,790 1,444 (1,432 – 1,455) 82,287 1,584 (1,571 – 1,596)
Testis cancer 1,848 51 (49 – 53) 1,876 50 (47 – 52) 2,019 50 (48 – 52) 2,011 47 (44 – 49)
* Rates are per 100,000 persons in the base populationB
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Table 2: Prevalence Rates and their Changes of 8 Urologic Conditions from 1999 to 2002, Primary Diagnosis by Selected Demographic Categories
     Prostate Cancer    Bladder Cancer       Kidney Cancer       Renal Mass
2002 Rate Change 2002 Rate Change 2002 Rate Change 2002 Rate Change
Total 5,434 (5,409 – 5,459) 4.0 943 (933 – 953) 0.5 233 (229 – 238) 7.4 1,584 (1,571 – 1,596) 31.0
Age
< 25 3 (-2 – 8) -62.9 21 (6 – 35) -50.5
25 – 34 11 (6 – 16) 10.6 76 (64 – 89) -16.2
35 – 44 94 (81 – 107) -26.6 50 (41 – 59) -37.3 35 (29 – 41) 6.0 171 (158 – 184) -2.3
45 – 54 605 (589 – 621) 11.7 158 (150 – 166) -15.3 98 (92 – 105) 0.3 357 (345 – 369) 3.5
55 – 64 2,280 (2,248 – 2,312) -7.8 443 (429 – 457) -18.7 192 (183 – 201) -1.8 722 (704 – 739) 2.9
65 – 74 8,038 (7,987 – 8,089) 3.1 1,314 (1,294 – 1,335) -0.9 375 (364 – 386) 5.1 2,478 (2,450 – 2,506) 30.2
75 – 84 11,614 (11,547 – 11,681) 5.9 2,042 (2,014 – 2,070) 7.7 419 (406 – 432) 17.8 3,692 (3,655 – 3,729) 43.0
85 + 11,336 (11,127 – 11,545) 18.0 2,134 (2,045 – 2,224) 21.4 296 (263 – 329) 6.9 4,075 (3,951 – 4,198) 52.6
Gender
Male 5,434 (5,409 – 5,459) 4.0 965 (954 – 975) 0.5 241 (236 – 246) 7.4 1,635 (1,622 – 1,648) 30.7
Female 243 (214 – 272) -3.2 71 (58 – 83) 10.6 462 (430 – 493) 53.4
Race-Ethnicity
White 6,318 (6,286 – 6,349) 3.7 1,222 (1,209 – 1,236) -0.6 297 (290 – 303) 8.9 2,019 (2,001 – 2,036) 33.9
Black 6,435 (6,360 – 6,511) 6.3 434 (414 – 453) -7.2 217 (204 – 230) 7.5 1,604 (1,570 – 1,639) 20.4
Hispanic 3,626 (3,498 – 3,753) 1.3 370 (330 – 410) 0.6 188 (161 – 215) 17.4 814 (758 – 870) 28.5
Other 4,163 (3,973 – 4,352) 8.1 507 (442 – 573) -8.8 214 (173 – 255) -4.3 1,431 (1,325 – 1,537) 26.1
Insurance Status
No ins/self-pay 4,145 (4,118 – 4,172) 2.7 708 (697 – 719) -0.9 186 (181 – 191) 5.7 1,105 (1,092 – 1,117) 22.7
Medicare 9,518 (9,444 – 9,592) -1.2 1,709 (1,678 – 1,739) -3.6 409 (394 – 424) 6.4 3,238 (3,196 – 3,280) 24.0
Medicaid 2,591 (2,061 – 3,121) 16.0 509 (280 – 739) -16.2 175 (47 – 302) 20.6 1,014 (706 – 1,322) 24.3
Private Ins/HMO 5,049 (4,989 – 5,109) -5.6 803 (780 – 826) -19.3 209 (197 – 221) -10.2 1,417 (1,387 – 1,447) 13.9
Other Insurance 2,261 (2,063 – 2,460) 3.0 379 (300 – 458) -19.4 116 (75 – 158) -36.5 642 (544 – 740) -0.4
Region
Northeast 6,508 (6,440 – 6,577) 3.4 1,222 (1,192 – 1,251) 3.6 275 (262 – 289) 4.4 1,682 (1,649 – 1,715) 37.7
Midwest 5,398 (5,339 – 5,457) 4.9 986 (962 – 1,011) 1.1 236 (225 – 248) 4.3 1,830 (1,798 – 1,862) 38.6
South 5,467 (5,427 – 5,506) 3.8 903 (887 – 918) 2.4 237 (230 – 245) 8.6 1,676 (1,656 – 1,696) 28.7
West 4,666 (4,624 – 4,709) -0.1 776 (759 – 793) -10.4 195 (187 – 203) 4.1 1,139 (1,119 – 1,158) 12.3B
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Interstitial Cystitis Prostatitis Erectile Dysfunction Urethral Stricture
2002 Rate Change 2002 Rate Change 2002 Rate Change 2002 Rate Change
Total 1,358 (1,347 – 1,370) 13.7 1,128 (1,118 – 1,139) -10.0 2,884 (2,867 – 2,901) 8.1 383 (377 – 389) -12.7
Age
< 25 439 (373 – 505) 8.1 144 (100 – 187) -5.0 270 (211 – 330) 34.1 21 (6 – 35) -57.6
25 – 34 490 (458 – 522) 0.6 256 (230 – 281) -17.1 662 (621 – 703) 45.7 62 (51 – 74) -10.5
35 – 44 503 (481 – 526) 1.6 394 (372 – 415) -17.3 1,506 (1,465 – 1,548) 32.2 83 (74 – 92) -21.4
45 – 54 410 (397 – 423) -3.5 571 (555 – 586) -14.9 2,983 (2,947 – 3,018) 19.1 129 (122 – 136) -18.9
55 – 64 559 (543 – 575) -15.5 787 (768 – 806) -18.6 3,585 (3,545 – 3,625) -1.9 211 (202 – 221) -26.0
65 – 74 1,934 (1,909 – 1,959) 15.5 1,833 (1,808 – 1,857) -6.7 3,906 (3,870 – 3,941) 5.2 547 (534 – 560) -13.9
75 – 84 3,028 (2,994 – 3,062) 22.6 1,720 (1,694 – 1,745) -8.5 2,204 (2,175 – 2,234) 6.2 839 (821 – 856) -6.9
85 + 3,349 (3,237 – 3,461) 37.8 1,305 (1,234 – 1,376) 1.2 926 (866 – 985) 19.8 1,047 (984 – 1,109) 0.1
Gender
Male 1,311 (1,300 – 1,323) 14.1 1,128 (1,118 – 1,139) -10.0 2,884 (2,867 – 2,901) 8.1 396 (390 – 403) -12.5
Female 2,205 (2,136 – 2,274) -2.4 98 (83 – 113) -25.2
Race-Ethnicity
White 1,735 (1,719 – 1,751) 13.9 1,383 (1,368 – 1,397) -9.7 3,059 (3,037 – 3,080) 7.1 474 (466 – 482) -9.8
Black 1,103 (1,074 – 1,131) 11.8 1,002 (974 – 1,030) -7.9 4,618 (4,557 – 4,678) 15.3 428 (410 – 445) -19.9
Hispanic 729 (676 – 782) -4.8 1,101 (1,035 – 1,167) -17.8 3,212 (3,099 – 3,324) 19.5 311 (277 – 346) -11.3
Other 1,018 (928 – 1,107) 5.7 999 (909 – 1,089) -7.7 2,647 (2,501 – 2,794) 4.7 284 (237 – 332) -17.5
Insurance Status
No ins/self-pay 1,017 (1,005 – 1,029) 9.0 918 (906 – 929) -14.0 2,709 (2,689 – 2,730) 9.6 290 (283 – 296) -15.3
Medicare 2,539 (2,502 – 2,577) 6.8 1,838 (1,806 – 1,870) -12.3 3,280 (3,237 – 3,323) 3.9 714 (694 – 734) -13.6
Medicaid 1,037 (726 – 1,348) -7.7 793 (512 – 1,074) -37.0 3,497 (2,907 – 4,087) 17.9 323 (150 – 497) -28.7
Private Ins/HMO 1,267 (1,238 – 1,295) 2.6 1,060 (1,033 – 1,087) -15.1 2,994 (2,949 – 3,038) -1.3 350 (335 – 365) -26.7
Other Insurance 633 (536 – 730) -0.2 768 (656 – 880) -13.7 3,723 (3,477 – 3,969) -4.2 224 (166 – 281) -14.3
Region
Northeast 1,858 (1,824 – 1,893) 15.5 996 (970 – 1,022) -7.7 2,471 (2,430 – 2,511) 6.5 397 (381 – 413) -7.0
Midwest 1,371 (1,344 – 1,399) 19.1 976 (952 – 1,000) -3.3 2,841 (2,800 – 2,882) 4.5 400 (385 – 415) -10.7
South 1,334 (1,316 – 1,352) 12.2 1348 (1,329 – 1,366) -12.2 3,118 (3,090 – 3,147) 14.6 402 (392 – 412) -16.5
West 1,030 (1,011 – 1,049) 0.7 980 (962 – 999) -13.0 2,825 (2,793 – 2,857) 2.8 329 (319 – 340) -14.2
* Rates per 100,000 persons in the base population. % change represents change in age-adjusted prevalence rates over 1999 – 2002.
Table 2: Prevalence Rates and their Changes of 8 Urologic Conditions from 1999 to 2002, Primary Diagnosis by Selected Demographic Categories (Continued)BMC Urology 2006, 6:30 http://www.biomedcentral.com/1471-2490/6/30
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South region had the highest prevalence and showed the
most rapid increase.
Rates and trends by data source
Table 3 shows age-adjusted prevalence rates for qualifying
conditions, computed based on the VHA data alone and
the combined VHA and Center for Medicare and Medicaid
Services (CMS) data for all VHA users. The percentage of
additional cases identified by adding CMS data varied
greatly by condition ranging from 21% (infertility in
2000) to 489% (posterior urethral valves in 2002).
Figure 1 shows percent distribution of patients by year
and source of data for the eight most prevalent conditions.
Age-adjusted prevalence rates of patients diagnosed by
Medicare providers alone increased significantly for five of
the eight conditions (except kidney cancer, prostatitis, and
urethral stricture), while the rates for all conditions diag-
nosed by both VHA and Medicare providers each year
remained unchanged and those diagnosed in VHA hospi-
tals alone actually decreased significantly for five condi-
tions (except bladder cancer, renal mass, and erectile
dysfunction). Thus, for example, there were only 4%
increase in overall age-adjusted prevalence rates for pros-
tate cancer between 1999 and 2002. The trends decom-
posed by data source however shows that the prevalence
among VHA users decreased by 12%, while that among
Medicare users increased by 20% (data not shown).
Discussion
Our results show a high and increasing prevalence of sev-
eral urologic conditions among VHA users. Among the
conditions we examined, most commonly listed as a pri-
mary diagnosis for VHA users were prostate cancer
(5.4%), erectile dysfunction (2.9%), renal mass (1.5%),
interstitial cystitis (1.4%), and prostatitis (1.1%) in 2002.
Many urologic conditions were diagnosed increasingly
more over the four-year study period. Erectile dysfunction
and renal mass showed the largest increases. In particular,
these two were the conditions commonly listed as second-
ary diagnoses, suggesting that these conditions were likely
diagnosed, evaluated and treated in non-urologic settings
in the context of other co-morbid conditions.
The increase in the prevalence of erectile dysfunction
coincides with the approval and availability of effective
oral therapies such as, sildenafil, in 1998 [18]. The VHA
started to cover sildenafil as a treatment option for erectile
dysfunction in 2001 [19,20]. Thus, the anticipation and
availability of this drug might have caused VHA users to
seek care for erectile dysfunction as a secondary diagnosis
when they see primary care providers.
The more than four-fold greater increase over time in the
prevalence of renal mass compared to kidney cancer (31%
versus 7%) may be attributed to more frequent use of
imaging studies (CT scans, ultrasounds, and MRI) for
non-urologic conditions. Future research is needed to
evaluate the increased health care costs and complications
associated with additional diagnostic evaluations versus
potential benefits of earlier and more frequent use of kid-
ney cancer screening and consequent identification of
renal masses.
While a diagnosis of prostatitis and urethral stricture
declined, prostate, bladder, and kidney cancers all showed
increasing trends in counts and crude rates over this
period. However, these trends appear to be mostly attrib-
utable to the aging of veterans. When the prevalence rates
were age-adjusted, the four-year trends were not statisti-
cally significant for any of these cancers.
Significant age, geographic, and racial variations in these
conditions were also observed. Variations by age groups
were consistent with expectation for all most prevalent
conditions. Another interesting finding was the consistent
pattern by which the VHA users in the Western region had
the lowest prevalence rates and smallest increases in many
of the urologic conditions. We do not know whether this
pattern is attributable to demographic composition of the
study population, to different practice patterns or the way
services are organized and provided across regions. These
patterns are not adjusted for other demographic factors
and co-morbidities and should be interpreted cautiously.
Further study is needed to understand the geographic var-
iations in the prevalence rates and their changes over time
of these urologic conditions.
Another key finding was the increasing proportions of
VHA users turning to Medicare hospitals for the diagnosis
of some urologic conditions. These trends were significant
for five of the eight most prevalent conditions even after
the rates were age-adjusted, suggesting that these trends
could not be explained by the aging of veterans. For exam-
ple, the VHA cared for 12% less prostate cancer patients,
while Medicare providers cared for 20% more, in 2002
than in 1999. A number of factors such as access to care
and financial concerns may have contributed to these
trends. Since these findings have important implications
in the resource use and management of these patients for
both the VHA and the CMS, the impact on disease preva-
lence and/or patterns of care for these patients warrants
further research.
As with any administrative database, limitations exist in
regard to the accuracy and completeness of the coded
information. Because VHA providers are not reimbursed
for a diagnosis or a treatment, less incentive may exist forBMC Urology 2006, 6:30 http://www.biomedcentral.com/1471-2490/6/30
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Table 3: Comparison of Age-Adjusted Prevalence Rates per 100,000 in the Base Population Based on VHA Data and VHA/CMS Data*
1999 Rates (95% CI)
VHA VHA/CMS % Change
Male reproductive health
Erectile Dysfunction 1,996 (1,982 – 2,011) 2,669 (2,652 – 2,685) 34
Peyronie's Disease 27 (26 – 29) 40 (38 – 42) 48
Infertility 62 (59 – 64) 75 (72 – 78) 21
Undescended Testis 4 (4 – 5) 7 (6 – 7) 75
Urethral diseases
Hypospadias 5 (4 – 5) 8 (7 – 9) 60
Stricture 244 (239 – 249) 439 (432 – 445) 80
Interstitial Cystitis 504 (497 – 511) 1,195 (1,184 – 1,206) 137
Prostatitis 579 (571 – 586) 1,254 (1,243 – 1,266) 117
Prostate cancer 2,843 (2,825 – 2,861) 5,226 (5,202 – 5,250) 84
Bladder Cancer 519 (511 – 526) 938 (928 – 948) 81
Kidney Cancer 131 (128 – 135) 217 (213 – 222) 66
Renal Mass 470 (463 – 477) 1,209 (1,198 – 1,220) 157
Testis cancer 40 (38 – 42) 51 (49 – 53) 28
2000 Rates (95% CI)
VHA VHA/CMS % Change
Male reproductive health
Erectile Dysfunction 2,073 (2,059 – 2,088) 2,790 (2,773 – 2,807) 35
Peyronie's Disease 26 (25 – 28) 40 (38 – 42) 54
Infertility 62 (59 – 64) 75 (72 – 77) 21
Undescended Testis 5 (4 – 5) 7 (6 – 7) 40
Urethral diseases
Hypospadias 4 (3 – 5) 7 (6 – 8) 75
Stricture 217 (212 – 222) 412 (406 – 418) 90
Interstitial Cystitis 504 (497 – 511) 1,256 (1,245 – 1,267) 149
Prostatitis 543 (536 – 551) 1,200 (1,189 – 1,211) 121
Prostate cancer 2,709 (2,692 – 2,727) 5,232 (5,208 – 5,256) 93
Bladder Cancer 467 (460 – 475) 926 (916 – 936) 98
Kidney Cancer 128 (125 – 132) 220 (215 – 224) 72
Renal Mass 462 (455 – 468) 1,317 (1,305 – 1,328) 185
Testis cancer 38 (36 – 40) 50 (47 – 52) 32BMC Urology 2006, 6:30 http://www.biomedcentral.com/1471-2490/6/30
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2001 Rates (95% CI)
VHA VHA/CMS % Change
Male reproductive health
Erectile Dysfunction 2,071 (2,057 – 2,086) 2,805 (2,788 – 2,822) 35
Peyronie's Disease 22 (20 – 23) 35 (33 – 37) 59
Infertility 61 (58 – 63) 76 (73 – 79) 25
Undescended Testis 4 (3 – 5) 7 (6 – 8) 75
Urethral diseases
Hypospadias 4 (3 – 5) 7 (6 – 8) 75
Stricture 186 (182 – 190) 387 (308 – 393) 108
Interstitial Cystitis 491 (484 – 498) 1,344 (1,332 – 1,355) 174
Prostatitis 502 (495 – 509) 1,204 (1,193 – 1,215) 140
Prostate cancer 2,611 (2,594 – 2,628) 5,373 (5,349 – 5,398) 106
Bladder Cancer 433 (426 – 440) 942 (932 – 952) 118
Kidney Cancer 122 (118 – 125) 227 (222 – 231) 86
Renal Mass 452 (445 – 458) 1,444 (1432 – 1,455) 219
Testis cancer 38 (36 – 40) 50 (48 – 52) 32
2002 Rates (95% CI)
VHA VHA/CMS % Change
Male reproductive health
Erectile Dysfunction 2,083 (2,069 – 2,098) 2,884 (2,867 – 2,901) 38
Peyronie's Disease 19 (18 – 21) 33 (31 – 35) 74
Infertility 59 (56 – 61) 74 (72 – 77) 25
Undescended Testis 3 (2 – 3) 5 (4 – 6) 67
Urethral diseases
Hypospadias 4 (3 – 4) 7 (6 – 7) 75
Stricture 166 (162 – 170) 383 (377 – 389) 131
Interstitial Cystitis 441 (435 – 448) 1,358 (1,347 – 1,370) 208
Prostatitis 442 (435 – 448) 1,128 (1,118 – 1,139) 155
Prostate cancer 2,505 (2,488 – 2,521) 5,434 (5,409 – 5,459) 117
Bladder Cancer 394 (387 – 400) 943 (933 – 953) 139
Kidney Cancer 118 (115 – 121) 233 (229 – 238) 97
Renal Mass 442 (436 – 449) 1,584 (1,571 – 1,596) 258
Testis cancer 35 (33 – 37) 47 (44 – 49) 34
* VHA indicates prevalence rates based on VHA data alone; VHA/CMS, prevalence rates based on VHA and Medicare Data.
Table 3: Comparison of Age-Adjusted Prevalence Rates per 100,000 in the Base Population Based on VHA Data and VHA/CMS Data* BMC Urology 2006, 6:30 http://www.biomedcentral.com/1471-2490/6/30
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them to fully code all conditions in contrast to Medicare
providers. Thus, our findings likely are conservative esti-
mates of disease prevalence and may be one explanation
why inclusion of Medicare data substantially increased
overall prevalence rates.
Conclusion
In conclusion, prevalence rates of several high priority
urologic diseases including prostate, bladder, kidney can-
cers, renal mass and erectile dysfunction are increasing in
veterans and show regional and racial variations. The
comparison of the VHA and the Medicare data shows dif-
ferent trends in prevalence of several urologic conditions.
Prevalence rates among veterans might be substantially
underestimated without using other administrative claims
data, including Medicare in combination with VHA data.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
MWS participated in the design of the study, oversaw sta-
tistical analyses of data, and drafted the manuscript.
HZ was responsible for data collection, management, sta-
tistical analysis, and edited the manuscript.
BCT participated in the design of the study, data analysis,
and edited the manuscript.
MJF participated in the interpretation of results, and
edited the manuscript.
Percent of Patients Diagnosed with a Qualifying Condition by Data Source, 1999 – 2002 Figure 1
Percent of Patients Diagnosed with a Qualifying Condition by Data Source, 1999 – 2002Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Urology 2006, 6:30 http://www.biomedcentral.com/1471-2490/6/30
Page 11 of 11
(page number not for citation purposes)
EY participated in the design of the study, the interpreta-
tion of results, and edited the manuscript.
CS participated in the design of the study, the interpreta-
tion of results, and edited the manuscript.
TJW oversaw the 2nd grant, participated in the design of
the study, the interpretation of results, and edited the
manuscript.
All authors read and approved the final manuscript.
Additional material
Acknowledgements
The authors gratefully acknowledge funding support from the Department 
of Veterans Affairs, Veterans Health Administration, Health Services 
Research and Development Service for providing infrastructure support 
and veterans' Medicare data (VA HSR&D SDR 98-004 VA Information 
Resource Center [VIReC] and XVA 69-001 and SDR 02-237 the VA Medi-
care Data Merge Initiative; Denise Hynes, Principal Investigator), and from 
the National Institute of Diabetes and Digestive and Kidney Diseases 
(NIDDK, An Intra-Agency Agreement for the Urologic Diseases in America 
Project; Timothy Wilt, VA Principal Investigator). The paper presents the 
findings and conclusions of the authors; it does not necessarily represent 
the Department of Veterans Affairs or Health Services Research and Devel-
opment Service or the NIDDK.
References
1. Calhoun EA, McNaughton CM, Pontari MA, O'Leary M, Leiby BE,
Landis RJ, Kusek JW, Litwin MS: The economic impact of chronic
prostatitis.  Arch Intern Med 2004, 164:1231-1236.
2. Litwin MS, Saigal CS, Beerbohm EM: The burden of urologic dis-
eases in America.  J Urol 2005, 173:1065-1066.
3. Litwin MS, Saigal CS, Yano EM, Avila C, Geschwind SA, Hanley JM,
Joyce GF, Madison R, Pace J, Polich SM, Wang M: Urologic diseases
in America Project: analytical methods and principal find-
ings.  J Urol 2005, 173:933-937.
4. Pearle MS, Calhoun EA, Curhan GC: Urologic diseases in Amer-
ica project: urolithiasis.  J Urol 2005, 173:848-857.
5. Litwin MS, Saigal CS: Urologic diseases in America: Interim Compendium
2004 [http://kidney.niddk.nih.gov/statistics/uda/
UDA_Introduction.pdf]. Washington, DC, US Department of Health
and Human Services
6. Richardson C, Waldrop J: Veterans: 2000.  http://www census gov/
prod/2003pubs/c2kbr-22 pdf 2005 [http://www.census.gov/prod/
2003pubs/c2kbr-22.pdf]. U.S. Census Bureau, Department of Com-
merce.
7. U.S. Department of Veterans Affairs: Annual Performance
Report FY 2000.  2000 [http://www.va.gov/budget/report/2000/
PerfRpt2000.pdf]. Washington, DC, U.S. Department of Veterans
Affairs
8. Murphy PA, Cowper DC, Seppala G, Stroupe KT, Hynes DM: Veter-
ans Health Administration inpatient and outpatient care
data: an overview.  Eff Clin Pract 2002, 5:E4.
9. Veterans Affairs Information Resource Center: VIReC Research
User Guide: FY2002 VHA Medical SAS Inpatient Datasets.
2003 [http://www.virec.research.va.gov/References/RUG/RUG-
Inpatient02.pdf]. Hines, IL, Edward J. Hines, Jr. Hospital
10. Veterans Affairs Information Resource Center: VIReC Research
User Guide: FY2002 VHA Medical SAS Outpatient Datasets.
2003 [http://www.virec.research.va.gov/References/RUG/RUG-
Outpatient02.pdf]. Hines, IL, Edward J. Hines, Jr. Hospital
11. Veterans Affairs Information Resource Center: Research findings from
the VA Medicare data merge initiative: veterans' enrollment, access and use
of Medicare and VA health services. 2003 [http://
www.virec.research.va.gov/DataSourcesName/VA-MedicareData/
USHreport.pdf]. Hines, IL, Edward J. Hines, Jr. VA Hospital
12. Hynes DM, Koelling K, Stroupe K, Arnold N, Sohn MW, al. : Access
and Use of Medicare and VA Services by Veterans.  Med Care
in press.
13. Sohn MW, Zhang H, Arnold N, Stroupe K, Taylor BC, Wilt TJ, Hynes
DM:  Transition to the new race/ethnicity data collection
standards in the Department of Veterans Affairs.  Popul Health
Metr 2006, 4:7.
14. U.S. Census Bureau: Statistical Abstracts of the United States 2006,
125th Edition Bureau of the Census, U.S. Department of Commerce;
2006. 
15. Klein RJ, Schoenborn CA: Age adjustment using the 2000 pro-
jected U.S. population.  Volume 20. Hyattsville, Maryland, National
Center for Health Statistics; 2001. 
16. Anderson RN, Rosenberg HM: Age standardization of death
rates: implementation of the year 2000 standard.  Volume
47(3). Hyattsville, Maryland, National Center for Health Statistics;
1998. 
17. Kuritz SJ, Landis JR, Koch GG: A general overview of Mantel-
Haenszel methods: applications and recent developments.
Annu Rev Public Health 1988, 9:123-160.
18. Nathan PH: A new era in the treatment of erectile dysfunc-
tion.  Am J Cardiol 1999, 84:18N-23N.
19. Fink HA, Mac DR, Rutks IR, Nelson DB, Wilt TJ: Sildenafil for male
erectile dysfunction: a systematic review and meta-analysis.
Arch Intern Med 2002, 162:1349-1360.
20. U.S. Department of Veterans Affairs Pharmacy Benefits Management-
Medical Advisory Panel: The primary care management of erec-
tile dysfunction.  1999, VHA PBM-SHG Publication No. 99-
1360:.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2490/6/30/prepub
Additional file 1
Appendix: List of Urologic Conditions, their Base Populations, and Meth-
ods of Identification. The table is an appendix and shows the list of uro-
logic conditions, their base populations, and methods of identification of 
conditions considered in the study.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2490-6-30-S1.doc]